Funding for this research was provided by:
Ministerstwo Nauki i Szkolnictwa Wyższego (641/N-TREAT/09/2010/0)
Received: 25 October 2020
Accepted: 9 March 2021
First Online: 24 March 2021
: This study was approved by the Ethics Committee of Medical University of Warsaw (BK/180/2008). Written informed consent was obtained from patients, or the parents or legal guardians of patients.
: Not applicable.
: Anna Lusakowska is a sub-investigator in clinical trials for patients with SMA (funded by Roche) and Duchenne muscular dystrophy (funded by PTC), receives institutional Grant support from Biogen, and is a lecturer on neuromuscular diseases supported by Biogen and Roche. Maria Jedrzejowska reports participation in scientific advisory boards for Biogen and Avexis/Novartis, receives honoraria for lectures from Biogen and travel support from Biogen and Roche, and acts as a sub-investigator in Roche trials of olesoxime and risdiplam for SMA. Anna Kaminska declares no conflicts of interest. Katarzyna Janiszewska declares no conflicts of interest. Przemysław Grochowski declares no conflicts of interest. Janusz Zimowski declares no conflicts of interest. Janusz Sierdzinski declares no conflicts of interest. Anna Kostera Pruszczyk reports lecture honoraria and travel support from Biogen, Roche, PTC, Avexis, and Novartis, institutional Grant support from Biogen, and advisory board honoraria from Biogen, Roche, Avexis, and Novartis, and is a principal investigator for Roche SMA studies.